CA2951280A1 - Treatment of severe hypertriglyceridemia - Google Patents

Treatment of severe hypertriglyceridemia Download PDF

Info

Publication number
CA2951280A1
CA2951280A1 CA2951280A CA2951280A CA2951280A1 CA 2951280 A1 CA2951280 A1 CA 2951280A1 CA 2951280 A CA2951280 A CA 2951280A CA 2951280 A CA2951280 A CA 2951280A CA 2951280 A1 CA2951280 A1 CA 2951280A1
Authority
CA
Canada
Prior art keywords
mbx
kit
composition
salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2951280A
Other languages
English (en)
French (fr)
Inventor
Pol Boudes
Yun-Jung Choi
Robert L. Martin
Charles A. Mcwherter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of CA2951280A1 publication Critical patent/CA2951280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2951280A 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia Abandoned CA2951280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
US62/017,444 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
CA2951280A1 true CA2951280A1 (en) 2015-12-30

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2951280A Abandoned CA2951280A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Country Status (16)

Country Link
US (1) US20150374649A1 (enExample)
EP (1) EP3160458A1 (enExample)
JP (1) JP2017519028A (enExample)
KR (1) KR20170020514A (enExample)
CN (1) CN106470675A (enExample)
AU (1) AU2015279905A1 (enExample)
BR (1) BR112016028918A2 (enExample)
CA (1) CA2951280A1 (enExample)
CL (1) CL2016003290A1 (enExample)
EA (1) EA201790091A1 (enExample)
HK (1) HK1231380A1 (enExample)
IL (1) IL249757A0 (enExample)
MX (1) MX2016017081A (enExample)
PH (1) PH12016502415A1 (enExample)
SG (1) SG11201610243YA (enExample)
WO (1) WO2015200580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA3085951C (en) * 2017-12-21 2022-10-11 Kowa Company, Ltd. Methods of treatment of hypertriglyceridemia
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors

Also Published As

Publication number Publication date
MX2016017081A (es) 2017-05-01
CL2016003290A1 (es) 2017-09-08
PH12016502415A1 (en) 2017-02-27
EP3160458A1 (en) 2017-05-03
SG11201610243YA (en) 2017-01-27
IL249757A0 (en) 2017-02-28
EA201790091A1 (ru) 2017-07-31
CN106470675A (zh) 2017-03-01
WO2015200580A1 (en) 2015-12-30
BR112016028918A2 (pt) 2017-08-22
AU2015279905A1 (en) 2017-02-02
JP2017519028A (ja) 2017-07-13
KR20170020514A (ko) 2017-02-22
US20150374649A1 (en) 2015-12-31
HK1231380A1 (zh) 2017-12-22

Similar Documents

Publication Publication Date Title
WO2015200580A1 (en) Treatment of severe hypertriglyceridemia
US11406611B2 (en) Treatment of intrahepatic cholestatic diseases
EA011637B1 (ru) Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт
CA3024155C (en) Low dose oral formulations of seladelpar and use thereof in the treatment of primary biliary cholangitis.
WO2006062933A2 (en) Stable compositions of fenofibrate with fatty acid esters
JP2010229099A (ja) 脂質異常症の改善または治療薬
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1262698A1 (en) Seladelpar for the treatment of primary biliary cholangitis
HK1262698B (en) Seladelpar for the treatment of primary biliary cholangitis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831